User login
Key clinical point: Patients with psoriasis who initiated biologics were more likely to develop psoriatic arthritis (PsA) than those who initiated phototherapy or oral therapy.
Major finding: The incidence rate of PsA regardless of exposure to any treatment was 9.75 per 1000 person-years vs. 77.26, 61.99, and 26.11 per 1000 person-years among initiators of biologics, oral therapy, and phototherapy, respectively. Patients receiving biologics were at a significantly higher risk of developing PsA vs. those receiving either oral or phototherapy (hazard ratio 4.48; 95% CI 4.23-4.75).
Study details: Findings are from a retrospective cohort study including 193,709 patients with psoriasis without PsA, of which 14,569 biologic and 20,321 cumulative oral and phototherapy initiations were identified.
Disclosures: R Fitzsimmons and A Ogdie received funding from National Psoriasis Foundation. Dr. Gelfand, T Love, and A Ogdie reported ties with several sources.
Source: Meer E et al. Ann Rheum Dis. 2021 Oct 6. doi: 10.1136/annrheumdis-2021-220761.
Key clinical point: Patients with psoriasis who initiated biologics were more likely to develop psoriatic arthritis (PsA) than those who initiated phototherapy or oral therapy.
Major finding: The incidence rate of PsA regardless of exposure to any treatment was 9.75 per 1000 person-years vs. 77.26, 61.99, and 26.11 per 1000 person-years among initiators of biologics, oral therapy, and phototherapy, respectively. Patients receiving biologics were at a significantly higher risk of developing PsA vs. those receiving either oral or phototherapy (hazard ratio 4.48; 95% CI 4.23-4.75).
Study details: Findings are from a retrospective cohort study including 193,709 patients with psoriasis without PsA, of which 14,569 biologic and 20,321 cumulative oral and phototherapy initiations were identified.
Disclosures: R Fitzsimmons and A Ogdie received funding from National Psoriasis Foundation. Dr. Gelfand, T Love, and A Ogdie reported ties with several sources.
Source: Meer E et al. Ann Rheum Dis. 2021 Oct 6. doi: 10.1136/annrheumdis-2021-220761.
Key clinical point: Patients with psoriasis who initiated biologics were more likely to develop psoriatic arthritis (PsA) than those who initiated phototherapy or oral therapy.
Major finding: The incidence rate of PsA regardless of exposure to any treatment was 9.75 per 1000 person-years vs. 77.26, 61.99, and 26.11 per 1000 person-years among initiators of biologics, oral therapy, and phototherapy, respectively. Patients receiving biologics were at a significantly higher risk of developing PsA vs. those receiving either oral or phototherapy (hazard ratio 4.48; 95% CI 4.23-4.75).
Study details: Findings are from a retrospective cohort study including 193,709 patients with psoriasis without PsA, of which 14,569 biologic and 20,321 cumulative oral and phototherapy initiations were identified.
Disclosures: R Fitzsimmons and A Ogdie received funding from National Psoriasis Foundation. Dr. Gelfand, T Love, and A Ogdie reported ties with several sources.
Source: Meer E et al. Ann Rheum Dis. 2021 Oct 6. doi: 10.1136/annrheumdis-2021-220761.